14 сент. 2022 г. · Using the Manitoba BMD database the authors concluded that PPI use did not appear to be associated with osteoporosis or with accelerated BMD ...

These impacts include an increased risk of fractures, the development of osteoporosis, and a decrease in bone mineral density (Lespessailles and Toumi, 2022).

One of the most significant medical concerns is the potential association of PPI use with increased risk for osteoporotic fractures including hip and vertebral ...

4 февр. 2013 г. · Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related ...

2 авг. 2023 г. · Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture; however, the mechanism is unclear.

Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, ...

The Bottom Line. Long-term use of proton pump inhibitors (PPIs) is not associated with changes in bone structure and strength that lead to fracture.

A growing body of evidence suggests a correlation between prolonged PPI use and an increased risk of bone fractures.

Long term PPI use is not associated with any changes in BMD or bone strength that would predispose to an increased risk of fracture. Shin ...